Antibody Directory

Researchers from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health (NIH), have identified a promising new target for autoimmune disease treatment - a cell-surface receptor called DR3.

Scientists in Victoria, Australia have developed a flu vaccine that has the potential to increase people's level of protection against common flu and the more deadly bird-flu. Victoria Minister of Innovation Gavin Jennings said the work of the Victorian researchers is featured in the Innovation corridor at this week's BIO International Conference. Mr. Jennings is at the conference as part of a Victorian contingent being led by Premier John Brumby.

A revitalised global effort to improve immunisation programmes and strengthen health systems in the poorest countries is saving an increasing number of lives and making a significant impact towards achieving the UN Millennium Development Goals.

Take Care Health Systems, one of the largest managers of convenient care clinics and a wholly-owned subsidiary of Walgreens (NYSE, NASDAQ: WAG), is now administering the shingles vaccine at all 177 Take Care Health Clinics located at Walgreens drugstores in 19 markets throughout 14 states. By administering the shingles vaccine in a convenient setting, Take Care Health Providers further extend access to high-quality, affordable and convenient health care to patients nationwide.

HIV/AIDS "prevention research has hit a major roadblock" because more than "150 recent prevention trials, including vaccine and microbicide candidates, failed to protect participants against HIV infection," Udo Schuklenk, a professor at Queen's University and the Ontario Research Chair in Bioethics and Public Policy, writes in an opinion piece in Toronto's

GlaxoSmithKline's (GSK) cervical cancer vaccine, Cervarix TM, was confirmed as the UK Department of Health's vaccine of choice for its national human papillomavirus (HPV) immunisation programme. The programme, which aims to protect against the two types of HPV that are responsible for approximately 70% of cervical cancers1, will start in September 2008 and will vaccinate girls aged 12 to 13 each year.

Rwandan first lady Jeannette Kagame last week at the United Nations in New York hosted a roundtable discussion about HIV/AIDS vaccine research and development, Rwanda's New Times reports. Kagame, who also serves as the high representative for the

Health care professionals should increase influenza immunization rates by implementing key, practice-proven interventions and offering vaccine at every opportunity throughout the entire influenza season, conclude leading influenza experts in a July 2008 supplement to The American Journal of Medicine.

invivodata inc., the industry leader in electronic patient reported outcomes (ePRO) solutions and services for global clinical research, today announced that its DiaryPRO® field-based ePRO system was used to capture primary efficacy endpoint data in the recently unblinded Phase III study of Pollinex® Quattro, a vaccine being developed by Allergy Therapeutics® plc (AIM:AGY) to treat the symptoms of seasonal allergic rhinoconjunctivitis (SAR).

Bavarian Nordic's cancer research unit, BN ImmunoTherapeutics, has completed an interim analysis of its first two clinical studies with MVA-BN(R)-HER2, a cancer vaccine immunotherapy for breast cancer patients. The first study, performed in the US, is evaluating MVA-BN(R)-HER2 treatment following chemotherapy and Herceptin(R) treatment.

A 52-year-old man with advanced metastatic melanoma, a deadly form of skin cancer, had a complete remission after being infused with billions of clones of his own CD4+ T tumor killer cells that had been cultured outside his body and "programmed" to attack a specific type of melanoma cancer cell. Experts are cautiously optimistic that breakthroughs like this are bringing us closer to the day when we regard cancer like diabetes, not curable, but controllable.

Overcoming resistance to a cancer drug Drugs that target members of the EGFR family of proteins have proven effective for the treatment of certain types of cancer, including breast cancer. However, in a large number of patients for whom the treatment initially works well, the tumor recurs and is resistant to the effects of the drug.

The immune system of vertebrate animals consists of two components: the innate immune response, a constitutive system ready to respond to a pathogen, and the adaptive immune response, a system of immunological memory that responds to previously encountered pathogens. In a study led by Dr.

To accelerate the translation of basic discoveries about HIV into advances in vaccine design and evaluation, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has formed a new Vaccine Discovery Branch within the Vaccine Research Program in the Division of AIDS (DAIDS).

A unique technique for analyzing the function of microRNAs developed by a Hebrew University of Jerusalem doctoral student has led to the discovery of a new mechanism by which viruses evade the human immune system. This discovery has important implications for human intervention in the battle between viruses and humans. For her work in this field, Naama Elefant, a student of Prof.

GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved KINRIX™ [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine], the first combination vaccine to offer protection against diphtheria, tetanus, pertussis and polio diseases in one shot.

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced that the U.S. Food and Drug Administration (FDA) has licensed Pentacel(R), Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine.

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today the inauguration of a high-tech vaccine production facility in France to respond to soaring demand worldwide. This new 100 million euros facility located in Val de Reuil (North West of France) incorporates the latest technology to produce vaccines that meet the highest standards of quality.

Oregano doesnÂ´t only give a Pizza its typical taste. Researchers at Bonn University and the ETH Zurich have discovered that this spice also contains a substance which, amongst other qualities, appears to help cure inflammations. The researchers administered its active ingredient - known as beta-caryophyllin (E-BCP) - to mice with inflamed paws. In seven out of ten cases there was a subsequent improvement in the symptoms.

A nasal spray that mimics our own natural defense system may be the answer to beating the common cold, according to a report in the latest issue of the Society of Chemical Industry's (SCI) magazine, Chemistry & Industry. The spray, being produced by the Califormia based company Novabay, contains an analogue of N-Chlorotaurine (NCT), a compound produced by white blood cells when they are attacked.

Treating cancer patients with interleukin-7 (IL-7), a small protein that can stimulate the immune system, leads to an increase in lymphocytes which are key to the production of effective immune responses in the body, according to a new study by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). The demonstration that IL-7 is able to broaden the possible immune responses in humans could have a wide range of clinical implications.

A breast cancer vaccine currently being tested in a Phase II trial has demonstrated to be safe and well tolerated in patients according to a paper to be published in the Journal of Clinical Oncology. The therapeutic breast cancer vaccine AE37 uses a peptide antigen (immune-stimulating fragment) of a cancer gene known as HER-2/neu. This gene/protein is present in many types of cells, but it is over-expressed in a high proportion of breast cancers as well as many others.

Bloomberg on Friday examined the current state of HIV vaccine research. The article also profiles Dennis Burton, professor of immunology at the Scripps Research Institute, and his research to develop an HIV vaccine.

The US Food and Drug Administration (FDA) announced yesterday that it had given approval for the first new combination vaccine for protecting 4 to 6 year old children against diphtheria, tetanus, pertussis and polio diseases in one shot, made by GlaxoSmithKline (GSK). The vaccine is branded as the trademarked name KINRIX, and its official long name is Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine.

Former MedImmune chief David Mott to leave AstraZeneca
Bizjournals.com, NC - 22 hours ago
... biologics unit and bringing another previous AstraZeneca acquisition, UK-based Cambridge Antibody Technology Group PLC, under its umbrella last fall. ...

Centocor requests OK for treatment
Chester DailyLocal.com, USA - 1 hour ago
Golimumab, Centocor's next-generation human anti-TNF-alpha monoclonal antibody, is being studied as an every four week subcutaneous injection and is also ...

Local partnerships recommended for Third Frontier grants from state
Akron Beacon Journal, OH - 21 hours ago
... in funding for commercialization of a liquid crystal-based antibody system for detecting common pathogens in water samples in as little as 30 minutes. ...

Novel Therapies for Melanoma
Medscape (subscription) - 18 hours ago
Dr. Wolchok: The efficacy data for ipilimumab, which is the antibody that is being jointly developed by Medarex and Bristol-Myers Squibb, has been quite ...

Centocor seeks OK for new arthritis drug
Bizjournals.com, NC - 20 hours ago
... application with the European Medicines Agency in February requesting the approval of golimumab, a monoclonal antibody, for the same indications. ...

Alzheimer's Drug Shows Early Promise
Washington Post, United States - 7 hours ago
Bapineuzumab is a humanized monoclonal antibody which binds to and might be able to eliminate beta amyloid peptide, which accumulate as plaques in the ...

dBTechno

Rapid HIV antibody test available
TheReporter.com, CA - 23 hours ago
Solano County Public Health will do its part for National HIV Testing Day today by offering the rapid HIV antibody test, OraQuick, at no charge. ...
Health Dept. promotes HIV testing BurlingtonFreePress.com
New HIV test free at LGH Lancaster Newspapers
all 165 news articles

Combination Therapy: A Real Advance for Cancer Patients with ...
Earthtimes (press release), UK - 19 hours ago
One is a "biological" therapy called rituximab (brand name Rituxan) -- an antibody that works by attacking certain types of immune cells (B cells) involved ...

USU researchers awarded $5.6 million NIH grant to fight deadly viruses
Genetic Engineering News (press release), NY - 17 hours ago
"We now have the critical resources needed to evaluate the therapeutic potential of both vaccines and perhaps more importantly a potent human antibody ...

A Look At The Spanish Press
Rundtownnews.co.uk, Spain - 21 hours ago
In 2006, the Basque Government commissioned an illustrator and writer to devise what was referred to as an "antibody," aimed at promoting the Basque ...

An article in the open-access journal PLOS ComputationalBiology discusses how statistical modeling can aidresearchers in determining a person's individual immune systemproteins. This will help to assess a patient's disease fighting abilityor the likelihood that the immune system will attack the body's owntissues. Although manyareas of research and medicine rely critically upon thisknowledge, obtaining this information is usually costly anddifficult.

The Advisory Committee for Immunization Practices (ACIP) recommended yesterday that flu shots be administered annually to children six months through 18 years of age. ACIP, functioning under the Centers for Disease Control and Prevention (CDC) umbrella, has been criticized for years by parents of vaccine-injured children for neglecting vaccine safety considerations in favor of keeping vaccination rates high.

"We have identified a key connection of signaling pathways in the cascade of events leading to sepsis. This defines a crucial point where the immune system spirals out of control to cause severe sepsis and where there is an opportunity for therapeutic intervention," says Scripps Research Professor Wolfram Ruf, who led the research with his postdoctoral fellow Frank Niessen. Their results are published in the February 27 advance, online issue of Nature.

Researchers at The Scripps Research Institute have developed a new two-punch strategy against HIV and they have already successfully tested aspects of it in the laboratory.Their study, which appears this week in the online Early Edition of the Proceedings of the National Academy of Sciences (PNAS), may re-energize attempts to create a preventive/therapeutic vaccine against HIV, say the authors.

It was announced that the U.S. Court of Federal Claims and the National Vaccine Injury Compensation Program ruled in favor of a child who regressed into autism as a result of vaccinations, several of which contained the mercury-based preservative thimerosal. Case documents state that the vaccines administered to the claimant significantly aggravated an underlying condition that ultimately led to regressive encephalopathy and symptoms of autism.

After the surgical removal of a malignant tumor, the chance that cancer will re-appear in a different location of the body remains high. But new research from Tel Aviv University, in a bold new field called Psychoneuroimmunology, may prevent those cancer cells from taking root again - and the key to the treatment is stress reduction.A new study led by Prof.

Researchers at Mayo Clinic and the Virginia Bioinformatics Institute (VBI) have received a second grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance understanding of the role of environmental fungi in chronic airway disorders. Recently NIAID awarded the researchers a further $1.8 million for these studies over a five-year period to investigate how the environmental fungus Alternaria triggers airway inflammation and bronchial asthma.

Now, a group of Scripps Research scientists have shown that EP2-19G2, one of a panel of fluorescent monoclonal antibodies that were first reported in 2000, produces its distinctive bright blue glow through a rare and highly complex recombination of electrical charge.This charge recombination involves an electron hole - the gap left by the electron as it is transferred from one molecule to the other.

The International AIDS Vaccine Initiative (IAVI) has announced the first award from its Innovation Fund, a new funding mechanism that will identify and advance potential breakthrough technologies and apply them in the AIDS vaccine research field. This initial project will apply an exciting new technology, a simulated human immune system the size of a small coin, which has the potential to predict human immune responses to new vaccines and drugs.

Five health prevention strategies could save more than 100,000 lives a year, according to recent research reported in the March issue of Mayo Clinic Women's HealthSource.Cost, busy schedules or just plain doctor avoidance prevent some people from seeking important preventive care. But skipping important screenings increases the risk of illness or having an illness diagnosed at a later stage when it's harder to treat or cure.

VGX Pharmaceuticals Inc. (VGX) announced that Professor David B. Weiner of the University of Pennsylvania will serve as the Chairman of the DNA Vaccines Asia 2008 Conference next week in Seoul, Korea. Professor Weiner is a pioneer in the field of DNA vaccines and a VGX co-founder. The conference-the first of such meetings in Asia-will bring together the pioneering scientists and thought leaders of DNA vaccines and therapies in Asia and the US.

Researchers at the University of Southern California (USC) have uncovered a new way to develop more effective tumor vaccines by turning off the suppression function of regulatory T cells. The results of the study, titled "A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression," will be published in Nature Medicine on March 2, 2008.

Receptor Logic, Ltd. has announced a partnership with sanofi pasteur, the vaccines division of sanofi-aventis Group, to develop T Cell Receptor Mimics (TCRm™) for the validation and testing of sanofi pasteur vaccines. Under a collaborative research and exclusive license agreement, Receptor Logic will create custom TCRm in support of sanofi pasteur's vaccine programs. Receptor Logic is funded and managed by life sciences venture firm, Emergent Technologies, Inc. (ETI).

Many areas of research and medicine rely critically upon knowing a person's individual immune system proteins, as they determine an individual's ability to fight disease or mistakenly attack their own tissues. However, obtaining this information is costly and difficult.

A panel of immunization experts voted to expand the recommended ages for annual influenza vaccination of children to include all children from 6 months through 18 years of age. The previous recommendation was for vaccination of children from 6 months to 59 months of age. The expanded recommendation is to take effect as soon as feasible, but no later than the 2009 - 2010 influenza season.